Triumvira Immunologics, an Austin, TX-based biotech, appointed Donna Rill to serve as chief technology officer. Triumvera said Rill will use her technology development and manufacturing experience to help drive the company’s clinical development programs to develop a platform for engineering T cells to attack cancers. The company’s lead drug, an experimental treatment for liquid tumors, is expected to start human testing in the first half of 2019. Previously, Rill was vice president of manufacturing for Cell Medica and chief development officer at Opexa Therapeutics.
Author: Angela Shah
Angela Shah was formerly the editor of Xconomy Texas. She has written about startups along a wide entrepreneurial spectrum, from Silicon Valley transplants to Austin transforming a once-sleepy university town in the '90s tech boom to 20-something women defying cultural norms as they seek to build vital IT infrastructure in a war-torn Afghanistan. As a foreign correspondent based in Dubai, her work appeared in The New York Times, TIME, Newsweek/Daily Beast and Forbes Asia.
Before moving overseas, Shah was a staff writer and columnist with The Dallas Morning News and the Austin American-Statesman. She has a Bachelor's of Journalism from the University of Texas at Austin, and she is a 2007 Knight-Wallace Fellow at the University of Michigan. With the launch of Xconomy Texas, she's returned to her hometown of Houston.
View all posts by Angela Shah
